Göbel K - Search Results

1

Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis.

Johnen A, Elpers C, Riepl E, Landmeyer NC, Krämer J, Polzer P, Lohmann H, Omran H, Wiendl H, Göbel K, Meuth SG. Johnen A, et al. Among authors: gobel k. Eur J Paediatr Neurol. 2019 Nov;23(6):783-791. doi: 10.1016/j.ejpn.2019.08.007. Epub 2019 Sep 5. Eur J Paediatr Neurol. 2019. PMID: 31540711

2

Advances in Multiple Sclerosis 2017.

Göbel K, Kleinschnitz C, Meuth SG. Göbel K, et al. Int J Mol Sci. 2018 Mar 19;19(3):901. doi: 10.3390/ijms19030901. Int J Mol Sci. 2018. PMID: 29562661 Free PMC article.

3

Long-term effects of dalfampridine in patients with multiple sclerosis.

Ruck T, Bittner S, Simon OJ, Göbel K, Wiendl H, Schilling M, Meuth SG. Ruck T, et al. Among authors: gobel k. J Neurol Sci. 2014 Feb 15;337(1-2):18-24. doi: 10.1016/j.jns.2013.11.011. Epub 2013 Nov 16. J Neurol Sci. 2014. PMID: 24290498

4

[Coagulation factors and multiple sclerosis : Key factors in the pathogenesis?].

Göbel K, Kleinschnitz C, Meuth SG. Göbel K, et al. Nervenarzt. 2018 Aug;89(8):908-912. doi: 10.1007/s00115-018-0491-7. Nervenarzt. 2018. PMID: 29404650 Review. German.

5

Upregulation of K2P5.1 potassium channels in multiple sclerosis.

Bittner S, Bobak N, Herrmann AM, Göbel K, Meuth P, Höhn KG, Stenner MP, Budde T, Wiendl H, Meuth SG. Bittner S, et al. Among authors: gobel k. Ann Neurol. 2010 Jul;68(1):58-69. doi: 10.1002/ana.22010. Ann Neurol. 2010. PMID: 20582984

6

Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis.

Meuth SG, Bittner S, Seiler C, Göbel K, Wiendl H. Meuth SG, et al. Among authors: gobel k. Mult Scler. 2011 Feb;17(2):198-203. doi: 10.1177/1352458510386998. Epub 2010 Dec 6. Mult Scler. 2011. PMID: 21135021

7

Immune therapy of multiple sclerosis--future strategies.

Meuth SG, Göbel K, Wiendl H. Meuth SG, et al. Among authors: gobel k. Curr Pharm Des. 2012;18(29):4489-97. doi: 10.2174/138161212802502198. Curr Pharm Des. 2012. PMID: 22612746 Review.

8

4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.

Göbel K, Wedell JH, Herrmann AM, Wachsmuth L, Pankratz S, Bittner S, Budde T, Kleinschnitz C, Faber C, Wiendl H, Meuth SG. Göbel K, et al. Exp Neurol. 2013 Oct;248:62-71. doi: 10.1016/j.expneurol.2013.05.016. Epub 2013 Jun 5. Exp Neurol. 2013. PMID: 23748135

9

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H. Schwab N, et al. Among authors: gobel k. Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925765

10

Prothrombin and factor X are elevated in multiple sclerosis patients.

Göbel K, Kraft P, Pankratz S, Gross CC, Korsukewitz C, Kwiecien R, Mesters R, Kehrel BE, Wiendl H, Kleinschnitz C, Meuth SG. Göbel K, et al. Ann Neurol. 2016 Dec;80(6):946-951. doi: 10.1002/ana.24807. Epub 2016 Nov 14. Ann Neurol. 2016. PMID: 27774643

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

118 results

Search Page